StockNews.com Initiates Coverage on Oragenics (NYSE:OGEN)

StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN) in a research note released on Wednesday. The brokerage issued a sell rating on the stock.

Oragenics Price Performance

Shares of NYSE OGEN opened at $0.28 on Wednesday. The stock has a market capitalization of $3.42 million, a PE ratio of -0.04 and a beta of 0.85. The business has a fifty day moving average price of $0.30 and a two-hundred day moving average price of $0.38. Oragenics has a fifty-two week low of $0.25 and a fifty-two week high of $3.43.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.